StockNews.com Initiates Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

Equities researchers at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

TCON opened at $0.03 on Tuesday. TRACON Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $14.75. The stock has a market capitalization of $109,802.00, a PE ratio of 0.01 and a beta of 1.37. The firm’s fifty day moving average price is $0.04 and its 200 day moving average price is $0.28.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.